DNA sequences of the papillomavirus HPV42 for use in diagnosis

• US 5,952,487 A
• Filed: 02/10/1994
• Issued: 09/14/1999
• Est. Priority Date: 06/28/1991
• Status: Expired due to Term

• Current Assignee: Roche Molecular Systems Inc (Roche Holding AG)
• Original Assignee: Institut Pasteur
• Inventors: Philipp, Wolfgang, Sapp, Martin, Cole, Stewart, Honore, Nadine
• Primary Examiner(s): Caputa, Anthony C.
• Assistant Examiner(s): HAYES, ROBERT CLINTON
• Application Number:
  US08/167,854
• Time in Patent Office: 2,042 Days
• Field of Search: 435/69.3, 536/23.72, 536/23.1, 536/24.32
• US Class Current: 536/23.72
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C12N 2710/20022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12Q 1/701 Specific hybridization probes
• CPC Class Codes: C12Q 1/708 for papilloma

Abstract

DNA sequences derived from human papillomavirus HPV42 are disclosed. Also disclosed are methods of using these sequences as hybridization probes in diagnostic assays.

Claims

1. Purified DNA derived from Human Papillomavirus 42 selected from the group consisting of:

(a) the nucleotide sequence shown in FIG. 1 (SEQ ID NO;

     1); and

(b) a nucleic acid sequence fully complementary to SEQ ID NO;

1.

2. A purified DNA selected from the group consisting of:

(a) a sequence consisting of nucleotide 476 to nucleotide 820 as set forth in FIG. 1 (SEQ ID NO;

     1);

(b) a sequence consisting of nucleotide 542 to nucleotide 820 as set forth in FIG. 1 (SEQ ID NO;

     1);

(c) a sequence fully complementary to the sequence set forth in (a); and

(d) a sequence fully complementary to the sequence set forth in (b).

3. A purified DNA selected from the group consisting of:

(a) a sequence consisting of nucleotide 108 to nucleotide 563 as set forth in FIG. 1 (SEQ ID NO;

     1);

(b) a sequence consisting of nucleotide 114 to nucleotide 563 as set forth in FIG. 1 (SEQ ID NO;

     1);

(c) a sequence fully complementary to the sequence set forth in (a); and

(d) a sequence fully complementary to the sequence set in (b).

4. A purified DNA selected from the group consisting of:

(a) a sequence consisting of nucleotide 724 to nucleotide as set forth in FIG. 1 (SEQ ID NO;

     1);

(b) a sequence consisting of nucleotide 829 to nucleotide as set forth in FIG. 1 (SEQ ID NO;

     1);

(c) a sequence fully complementary to the sequence set in (a); and

(d) a sequence fully complementary to the sequence set in (b).

5. A purified DNA selected from the group consisting of:

(a) a sequence consisting of nucleotide 2672 to nucleotide as set forth in FIG. 1 (SEQ ID NO;

     1);

(b) a sequence consisting of nucleotide 2702 to nucleotide as set forth in FIG. 1 (SEQ ID NO;

     1);

(c) a sequence fully complementary to the sequence set in (a); and

(d) a sequence fully complementary to the sequence set in (b).

6. A purified DNA selected from the group consisting of:

(a) a sequence consisting of nucleotide 3282 to nucleotide as set forth in FIG. 1 (SEQ ID NO;

     1); and

(b) a sequence fully complementary to the sequence set forth in (a).

7. A purified DNA selected from the group consisting of:

(a) a sequence consisting of nucleotide 3919 to nucleotide 4203 as set forth in FIG. 1 (SEQ ID NO;

     1); and

(b) a sequence fully complementary to the sequence set forth in (a).

8. A purified DNA selected from the group consisting of:

(a) a sequence consisting of nucleotide 4348 to nucleotide 5853 as set forth in FIG. 1 (SEQ ID NO;

     1);

(b) a sequence consisting of nucleotide 4423 to nucleotide 5853 as set forth in FIG. 1 (SEQ ID NO;

     1);

(c) a sequence fully complementary to the sequence set forth in (a); and

(d) a sequence fully complementary to the sequence set forth in (b).

9. A purified DNA selected from the group consisting of:

(a) a sequence consisting of nucleotide 5756 to nucleotide 7342 as set forth in FIG. 1 (SEQ ID NO;

     1);

(b) a sequence consisting of nucleotide 5837 to nucleotide 7342 as set forth in FIG. 1 (SEQ ID NO;

     1);

(c) a sequence fully complementary to the sequence set forth in (a); and

(d) a sequence fully complementary to the sequence set forth in (b).